Login to Your Account



GTx, Ortho Biotech SARM Deal Could Grow To More Than $82M

By Karen Pihl-Carey


Thursday, March 18, 2004
Less than two months after conducting its initial public offering, GTx Inc. found a potential dream deal for an early clinical program focused on selective androgen receptor modulators (SARMs). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription